|
|
|
|
LEADER |
00000cam a2200000Mi 4500 |
001 |
SCIDIR_ocn774290275 |
003 |
OCoLC |
005 |
20231117044702.0 |
006 |
m o d |
007 |
cr cn||||||||| |
008 |
111221s2012 enkaf ob 001 0 eng d |
040 |
|
|
|a E7B
|b eng
|e pn
|e rda
|c E7B
|d OPELS
|d N$T
|d CDX
|d YDXCP
|d OCLCQ
|d OCLCF
|d OCLCQ
|d UAB
|d MEU
|d OCLCQ
|d OL$
|d UKBTH
|d OCLCO
|d OCLCQ
|d OCLCO
|
019 |
|
|
|a 1113790510
|
020 |
|
|
|a 9780123945969
|q (electronic bk.)
|
020 |
|
|
|a 0123945968
|q (electronic bk.)
|
020 |
|
|
|a 9780123948311
|q (electronic bk.)
|
020 |
|
|
|a 0123948312
|q (electronic bk.)
|
020 |
|
|
|a 1283348055
|
020 |
|
|
|a 9781283348058
|
020 |
|
|
|a 9786613348050
|
020 |
|
|
|a 6613348058
|
035 |
|
|
|a (OCoLC)774290275
|z (OCoLC)1113790510
|
050 |
|
4 |
|a RB113
|b .A55 2012eb
|
072 |
|
7 |
|a SCI
|x 056000
|2 bisacsh
|
082 |
0 |
4 |
|a 571.9/4
|2 23
|
245 |
0 |
0 |
|a Animal Models of Molecular Pathology /
|c edited by P. Michael Conn.
|
264 |
|
1 |
|a London :
|b Elsevier,
|c 2012.
|
300 |
|
|
|a 1 online resource (xv, 454 pages, 8 unnumbered pages of plates) :
|b illustrations (some color).
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Progress in molecular biology and translational science,
|x 1877-1173 ;
|v v. 105
|
546 |
|
|
|a Text in English.
|
504 |
|
|
|a Includes bibliographical references and index.
|
520 |
|
|
|a This volume explores some of the most exciting recent advances in basic research on animal models of molecular pathology.
|
505 |
0 |
|
|a Front Cover; Animal Models of Molecular Pathology; Copyright; Contents; Contributors; Preface; Animal Models of Atherosclerosis; I. Atherosclerosis Development: Basic Concepts; II. Animal Models of Atherosclerosis; A. Rabbit Models of Atherosclerosis; B. Swine Models of Atherosclerosis; C. Nonhuman Primate Models of Atherosclerosis; D. Rodent Models of Atherosclerosis; III. Concluding Remarks; Acknowledgments; References; Genetic Animal Models of Cerebral Vasculopathies; I. Cerebral Amyloid Angiopathy; A. Clinical Overview; B. Molecular Biology; C. Animal Models for CAA
|
505 |
8 |
|
|a D. Insights into Pathophysiology from Transgenic ModelsII. Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL); A. Clinical Overview; B. Molecular Biology; C. Animal Models of CADASIL; a. R90C Mice; b. C428S Mice; c. R169C Mice; d. R142C Mice; e. R1031C and C455R; D. Insights into Pathophysiology from Transgenic Models; III. Concluding Remarks; Acknowledgments; References; Experimental Models of Seizures and Epilepsies; I. Introduction; II. Classification of Epileptic Seizures; A. Focal Onset Seizures; B. Generalized Onset Seizures
|
505 |
8 |
|
|a C. Seizures of Unknown OriginIII. Classification of Epileptic Syndromes; IV. Models for Seizures and Epilepsies; A. The Perfect Animal Model; B. Chemical Models; C. Electrical Stimulation Models; D. Genetic Models; E. Developmental Models; F. Trauma Models; G. Emerging Epilepsy Models; V. Summary; References; Animal Models of Muscular Dystrophy; I. Dystrophin; A. Mouse Models for Duchenne Muscular Dystrophy; B. Canine Models for DMD; II. The Sarcoglycans; A. delta-Sarcoglycan and LGMD2F; B. gamma-Sarcoglycan and LGMD2C; C. beta-Sarcoglycan and LGMD2E; D. a-Sarcoglycan and LGMD2D
|
505 |
8 |
|
|a E. Canine Models of Sarcoglycan DeficiencyIII. Calcium and Dystrophic Pathology; A. Calcium Contributes to the Pathology of Dystrophic Skeletal Muscles; B. Dysferlin Gene Mutations; C. Calpain 3 and LGMD2A; D. Titin and LGMD2J; IV. a-Actinin; V. Fukutin-Related Protein and Dystroglycan Processing; VI. Desmin; VII. Laminin a2; VIII. Collagen VI; IX. D4Z4 Repeats and FSHD; X. DMPK and Myotonic Dystrophy; XI. Conclusions; Acknowledgments; References; Acute Phase Proteins in Animals; I. The Acute Phase Response; A. Innate Immunity; B. Induction of the APR; C. Other Effects of the APR
|
505 |
8 |
|
|a II. Acute Phase ProteinsA. C-Reactive Protein; B. Serum Amyloid A; C. Haptoglobin; D. Other APP; E. Negative Acute Phase Proteins; F. Quantitation of APP; III. Clinical Value of APP; A. Comparison to Other Markers of APR; B. Diagnosis; C. Prognosis; D. Subclinical Disease; E. Stress; F. Chronic Inflammation; IV. APP in Animals; A. Rodents and Rabbits; B. Companion Animals; C. Large Animals; D. Avian, Exotic, and Wildlife Species; V. Concluding Remarks; References; Animal Models of Hemophilia; I. The Hemophilia A Mice; A. Hemophilia A; B. The Hemophilia A Mouse Model
|
650 |
|
0 |
|a Pathology, Molecular.
|
650 |
|
2 |
|a Pathology, Molecular
|0 (DNLM)D057089
|
650 |
|
6 |
|a Pathologie mol�eculaire.
|0 (CaQQLa)201-0062220
|
650 |
|
7 |
|a SCIENCE
|x Life Sciences
|x Anatomy & Physiology.
|2 bisacsh
|
650 |
|
7 |
|a Pathology, Molecular
|2 fast
|0 (OCoLC)fst01054980
|
700 |
1 |
|
|a Conn, P. Michael,
|e editor.
|
830 |
|
0 |
|a Progress in molecular biology and translational science ;
|v v. 105.
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780123945969
|z Texto completo
|